|
|
|
Posted 18 July 2024 PM
A Brisbane biotech looking to shake-up the anaphylaxis market with an inhaler has expanded an existing partnership with US-based Catalent, leveraging the company's "commercial expertise".
De Motu Cordis (DMC), founded by Professor John Fraser, is developing DMC-IH1, an inhaled epinephrine product for the emergency treatment of anaphylaxis using a dry powder inhaler.
Epinephrine is the only proven treatment for anaphylaxis with currently available treatments administered via intramuscular injection, such as the widely-used and genericised EpiPen, sponsored by Alphapharm in Australia.
The partnership plans with Catalent, a Contract Development and Manufacturing Organisation (CDMO), include services from drug product manufacturing and device assembly to commercial launch of DMC-IH1.
 |
| DMC inhaler for anaphylaxis |
Catalent dry powder inhaler drug delivery services offer end-to-end solutions to bring customers through the entire clinical pharma journey by leveraging the commercial expertise and specialty product depth across the company's network of sites.
"We are excited to build on our partnership with Catalent, one of the world's leading CDMOs, and look forward to Catalent's team supporting our ability to further advance DMC-IH1, through support for drug product manufacture and dry powder inhaler assembly," CEO of DMC, Peter O'Neill, said.
"Catalent provides DMC with a consistency of quality and manufacturing excellence in the United States to service global markets."
The most recent plans build upon the original partnership between Catalent and DMC, initiated in November 2022.
While DMC-IH1 is still in early development, the biotech touts that patients' plasma epinephrine concentrations reached Cmax eight times faster with its inhaler than EpiPen in a Phase 1 clinical trial.
Since inception, DMC has raised over US$21m in Seed rounds primarily in Australia.
"The majority of funding to date has been secured via the Queensland Business Development Fund, high net worth individuals and Australian family offices," according to DMC.
A Series A financing round is planned for the first half of 2025, which will "ideally be anchored by a US based VC," the company added.
Tiffany Walker
If you were passed this article by a colleague, chances are you've missed other important Pharma in Focus articles and features.
To find out more, go to www.pharmainfocus.com.au and sign up for a FREE Full Text trial
Pharma in Focus
Australia's most trusted source of pharma news
© Copyright Lush Media. End of News - printed 15 January 2026